secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0000950170-25-090405
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform
--------------------------------------------------------------------------------

- CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.
- CRN10329 (SST3 agonist) reduced cystic index, kidney weight, and injury markers in ADPKD mouse model; SST3 highly expressed in cyst-lining cells.
- CRN09682 (NDC) showed dose-dependent anti-tumor activity in mouse models; free MMAE persisted in tumor >240 hours, cleared from plasma by 24 hours.
- Phase 1/2 BRAVESST2 trial of CRN09682 expects up to 150 participants; Phase 1 dose escalation: 3-6 patients per cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/0000950170-25-090405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025090405/crnx-20250626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-090405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer